Metformin reverses oxidative stress‑induced mitochondrial dysfunction in pre‑osteoblasts via the EGFR/GSK‑3β/calcium pathway

Cao,Fangming; Yang,Keda; Qiu,Shui; Li,Jie; Jiang,Wen; Tao,Lin; Zhu,Yue

doi:10.3892/ijmm.2023.5239

Metformin reverses oxidative stress‑induced mitochondrial dysfunction in pre‑osteoblasts via the EGFR/GSK‑3β/calcium pathway

Authors:
- Fangming Cao
- Keda Yang
- Shui Qiu
- Jie Li
- Wen Jiang
- Lin Tao
- Yue Zhu
View Affiliations

Affiliations: Department of Orthopedics, First Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China
Published online on: March 27, 2023 https://doi.org/10.3892/ijmm.2023.5239
Article Number: 36
Copyright: © Cao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Oxidative stress is one of the main causes of osteoblast apoptosis induced by post‑menopausal osteoporosis. The authors previously found that metformin can reverse the loss of bone mass in post‑menopausal osteoporosis. The present study aimed to further clarify the effects and mechanisms of action of metformin in post‑menopausal osteoporosis under conditions of oxidative stress. Combined with an in‑depth investigation using the transcriptome database, the association between oxidative stress and mitochondrial dysfunction in post‑menopausal osteoporosis was confirmed. A pre‑osteoblast model of oxidative stress was constructed, and the apoptotic rate following the addition of hydrogen peroxide and metformin was detected using CCK‑8 assay and Annexin V‑FITC/PI staining. Mitochondrial membrane potential was detected using the JC‑1 dye, the intracellular calcium concentration was detected using Fluo‑4 AM, the intracellular reactive oxygen species (ROS) level was observed using DCFH‑DA, and the mitochondrial superoxide level was observed using MitoSOX Red. Bay K8644 was used to increase the level of intracellular calcium. siRNA was used to interfere with the expression of glycogen synthase kinase (GSK)‑3β. Western blot analysis was used to detect the expression of mitochondrial dysfunction‑related proteins. The results revealed that oxidative stress decreased mitochondrial membrane potential and increased intracellular ROS, mitochondrial superoxide and cytoplasmic calcium levels in pre‑osteoblasts; however, metformin improved mitochondrial dysfunction and reversed oxidative stress‑induced injury. Metformin inhibited mitochondrial permeability transition pore opening, suppressed the cytoplasmic calcium influx and reversed pre‑osteoblast apoptosis by promoting GSK‑3β phosphorylation. Moreover, it was found that EGFR was the cell membrane receptor of metformin in pre‑osteoblasts, and the EGFR/GSK‑3β/calcium axis played a key role in metformin reversing the oxidative stress response of pre‑osteoblasts in post‑menopausal osteoporosis. On the whole, these findings provide a pharmacological basis for the use of metformin for the treatment of post‑menopausal osteoporosis.

View Figures

View References

1	Bandeira L and Bilezikian JP: Novel therapies for postmenopausal osteoporosis. Endocrinol Metab Clin North Am. 46:207–219. 2017. View Article : Google Scholar : PubMed/NCBI
2	Kanis JA, Cooper C, Rizzoli R and Reginster JY; Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis (ESCEO) and the Committees of Scientific Advisors and National Societies of the International Osteoporosis Foundation (IOF): European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 30:3–44. 2019. View Article : Google Scholar
3	Black DM and Rosen CJ: Clinical practice. Postmenopausal osteoporosis. N Engl J Med. 374:254–262. 2016. View Article : Google Scholar : PubMed/NCBI
4	Kespohl B, Schumertl T, Bertrand J, Lokau J and Garbers C: The cytokine interleukin-11 crucially links bone formation, remodeling and resorption. Cytokine Growth Factor Rev. 60:18–27. 2021. View Article : Google Scholar : PubMed/NCBI
5	Appelman-Dijkstra NM and Papapoulos SE: Modulating bone resorption and bone formation in opposite directions in the treatment of postmenopausal osteoporosis. Drugs. 75:1049–1058. 2015. View Article : Google Scholar : PubMed/NCBI
6	Li J, Li X, Liu D, Hamamura K, Wan Q, Na S, Yokota H and Zhang P: eIF2α signaling regulates autophagy of osteoblasts and the development of osteoclasts in OVX mice. Cell Death Dis. 10:9212019. View Article : Google Scholar
7	Zhao F, Guo L, Wang X and Zhang Y: Correlation of oxidative stress-related biomarkers with postmenopausal osteoporosis: A systematic review and meta-analysis. Arch Osteoporos. 16:42021. View Article : Google Scholar : PubMed/NCBI
8	Mohamad NV, Ima-Nirwana S and Chin KY: Are oxidative stress and inflammation mediators of bone loss due to estrogen deficiency? A review of current evidence. Endocr Metab Immune Disord Drug Targets. 20:1478–1487. 2020. View Article : Google Scholar : PubMed/NCBI
9	Vatner SF, Zhang J, Oydanich M, Berkman T, Naftalovich R and Vatner DE: Healthful aging mediated by inhibition of oxidative stress. Ageing Res Rev. 64:1011942020. View Article : Google Scholar : PubMed/NCBI
10	Sies H and Jones DP: Reactive oxygen species (ROS) as pleiotropic physiological signalling agents. Nat Rev Mol Cell Biol. 21:363–383. 2020. View Article : Google Scholar : PubMed/NCBI
11	Wang FS, Wu RW, Chen YS, Ko JY, Jahr H and Lian WS: Biophysical modulation of the mitochondrial metabolism and redox in bone homeostasis and osteoporosis: How biophysics converts into bioenergetics. Antioxidants (Basel). 10:13942021. View Article : Google Scholar : PubMed/NCBI
12	Khosla S and Hofbauer LC: Osteoporosis treatment: Recent developments and ongoing challenges. Lancet Diabetes Endocrinol. 5:898–907. 2017. View Article : Google Scholar : PubMed/NCBI
13	Arceo-Mendoza RM and Camacho PM: Postmenopausal osteoporosis: Latest guidelines. Endocrinol Metab Clin North Am. 50:167–178. 2021. View Article : Google Scholar : PubMed/NCBI
14	Ensrud KE: Bisphosphonates for postmenopausal osteoporosis. JAMA. 325:962021. View Article : Google Scholar : PubMed/NCBI
15	Buckley L, Guyatt G, Fink HA, Cannon M, Grossman J, Hansen KE, Humphrey MB, Lane NE, Magrey M, Miller M, et al: 2017 American college of rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheumatol. 69:1521–1537. 2017. View Article : Google Scholar : PubMed/NCBI
16	Reid IR: A broader strategy for osteoporosis interventions. Nat Rev Endocrinol. 16:333–339. 2020. View Article : Google Scholar : PubMed/NCBI
17	Lv Z and Guo Y: Metformin and its benefits for various diseases. Front Endocrinol (Lausanne). 11:1912020. View Article : Google Scholar : PubMed/NCBI
18	Foretz M, Guigas B, Bertrand L, Pollak M and Viollet B: Metformin: From mechanisms of action to therapies. Cell Metab. 20:953–966. 2014. View Article : Google Scholar : PubMed/NCBI
19	Tseng CH: Metformin use is associated with a lower risk of osteoporosis/vertebral fracture in Taiwanese patients with type 2 diabetes mellitus. Eur J Endocrinol. 184:299–310. 2021. View Article : Google Scholar
20	Jiating L, Buyun J and Yinchang Z: Role of metformin on osteoblast differentiation in type 2 diabetes. Biomed Res Int. 2019:92039342019. View Article : Google Scholar : PubMed/NCBI
21	Wang X, Sun Q, Jiang Q, Jiang Y, Zhang Y, Cao J, Lu L, Li C, Wei P, Wang Q and Wang Y: Cryptotanshinone ameliorates doxorubicin-induced cardiotoxicity by targeting Akt-GSK-3β-mPTP pathway in vitro. Molecules. 26:14602021. View Article : Google Scholar
22	Yang K, Cao F, Qiu S, Jiang W, Tao L and Zhu Y: Metformin promotes differentiation and attenuates H2O2-induced oxidative damage of osteoblasts via the PI3K/AKT/Nrf2/HO-1 pathway. Front Pharmacol. 13:8298302022. View Article : Google Scholar :
23	Yang K, Pei L, Zhou S, Tao L and Zhu Y: Metformin attenuates H₂O₂-induced osteoblast apoptosis by regulating SIRT3 via the PI3K/AKT pathway. Exp Ther Med. 22:13162021. View Article : Google Scholar
24	Bai J, Xie N, Hou Y, Chen X, Hu Y, Zhang Y, Meng X, Wang X and Tang C: The enhanced mitochondrial dysfunction by cantleyoside confines inflammatory response and promotes apoptosis of human HFLS-RA cell line via AMPK/Sirt 1/NF-κB pathway activation. Biomed Pharmacother. 149:1128472022. View Article : Google Scholar
25	Zhang R, Li G, Zhang Q, Tang Q, Huang J, Hu C, Liu Y, Wang Q, Liu W, Gao N and Zhou S: Hirsutine induces mPTP-dependent apoptosis through ROCK1/PTEN/PI3K/GSK3β pathway in human lung cancer cells. Cell Death Dis. 9:5982018. View Article : Google Scholar
26	Roskoski R Jr: Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers. Pharmacol Res. 139:395–411. 2019. View Article : Google Scholar
27	Wang S, Zhang Y, Wang Y, Ye P, Li J, Li H, Ding Q and Xia J: Amphiregulin confers regulatory T cell suppressive function and tumor invasion via the EGFR/GSK-3β/Foxp3 axis. J Biol Chem. 291:21085–21095. 2016. View Article : Google Scholar : PubMed/NCBI
28	Sanchez-Rangel E and Inzucchi SE: Metformin: Clinical use in type 2 diabetes. Diabetologia. 60:1586–1593. 2017. View Article : Google Scholar : PubMed/NCBI
29	Cameron AR, Morrison VL, Levin D, Mohan M, Forteath C, Beall C, McNeilly AD, Balfour DJ, Savinko T, Wong AK, et al: Anti-inflammatory effects of metformin irrespective of diabetes status. Circ Res. 119:652–665. 2016. View Article : Google Scholar : PubMed/NCBI
30	Yang TC, Duthie GG, Aucott LS and Macdonald HM: Vitamin E homologues α- and γ-tocopherol are not associated with bone turnover markers or bone mineral density in peri-menopausal and post-menopausal women. Osteoporos Int. 27:2281–2290. 2016. View Article : Google Scholar : PubMed/NCBI
31	Kulkarni AS, Gubbi S and Barzilai N: Benefits of metformin in attenuating the hallmarks of aging. Cell Metab. 32:15–30. 2020. View Article : Google Scholar : PubMed/NCBI
32	Zhang T, Liu Q, Gao W, Sehgal SA and Wu H: The multifaceted regulation of mitophagy by endogenous metabolites. Autophagy. 18:1216–1239. 2022. View Article : Google Scholar :
33	Abate M, Festa A, Falco M, Lombardi A, Luce A, Grimaldi A, Zappavigna S, Sperlongano P, Irace C, Caraglia M and Misso G: Mitochondria as playmakers of apoptosis, autophagy and senescence. Semin Cell Dev Biol. 98:139–153. 2020. View Article : Google Scholar
34	Panel M, Ghaleh B and Morin D: Mitochondria and aging: A role for the mitochondrial transition pore? Aging Cell. 17:e127932018. View Article : Google Scholar : PubMed/NCBI
35	Wu Y, Yang M, Fan J, Peng Y, Deng L, Ding Y, Yang R, Zhou J, Miao D and Fu Q: Deficiency of osteoblastic Arl6ip5 impaired osteoblast differentiation and enhanced osteoclastogenesis via disturbance of ER calcium homeostasis and induction of ER stress-mediated apoptosis. Cell Death Dis. 5:e14642014. View Article : Google Scholar : PubMed/NCBI
36	Zhu P, Hu S, Jin Q, Li D, Tian F, Toan S, Li Y, Zhou H and Chen Y: Ripk3 promotes ER stress-induced necroptosis in cardiac IR injury: A mechanism involving calcium overload/XO/ROS/mPTP pathway. Redox Biol. 16:157–168. 2018. View Article : Google Scholar : PubMed/NCBI
37	NavaneethaKrishnan S, Rosales JL and Lee KY: mPTP opening caused by Cdk5 loss is due to increased mitochondrial Ca²⁺ uptake. Oncogene. 39:2797–2806. 2020. View Article : Google Scholar : PubMed/NCBI
38	Nagini S, Sophia J and Mishra R: Glycogen synthase kinases: Moonlighting proteins with theranostic potential in cancer. Semin Cancer Biol. 56:25–36. 2019. View Article : Google Scholar
39	Lal H, Ahmad F, Woodgett J and Force T: The GSK-3 family as therapeutic target for myocardial diseases. Circ Res. 116:138–149. 2015. View Article : Google Scholar : PubMed/NCBI
40	Morciano G, Naumova N, Koprowski P, Valente S, Sardão VA, Potes Y, Rimessi A, Wieckowski MR and Oliveira PJ: The mitochondrial permeability transition pore: An evolving concept critical for cell life and death = The GSK-3 family as therapeutic target for myocardial diseases. Biol Rev Camb Philos Soc. 96:2489–2521. 2021. View Article : Google Scholar : PubMed/NCBI
41	Karch J, Bround MJ, Khalil H, Sargent MA, Latchman N, Terada N, Peixoto PM and Molkentin JD: Inhibition of mitochondrial permeability transition by deletion of the ANT family and CypD. Sci Adv. 5:eaaw45972019. View Article : Google Scholar : PubMed/NCBI
42	Wang H, Ai J, Shopit A, Niu M, Ahmed N, Tesfaldet T, Tang Z, Li X, Jamalat Y, Chu P, et al: Protection of pancreatic β-cell by phosphocreatine through mitochondrial improvement via the regulation of dual AKT/IRS-1/GSK-3β and STAT3/Cyp-D signaling pathways. Cell Biol Toxicol. 38:531–551. 2022. View Article : Google Scholar
43	Hu Z, Crump SM, Zhang P and Abbott GW: Kcne2 deletion attenuates acute post-ischaemia/reperfusion myocardial infarction. Cardiovasc Res. 110:227–237. 2016. View Article : Google Scholar : PubMed/NCBI
44	Ding L and Billadeau DD: Glycogen synthase kinase-3β: A novel therapeutic target for pancreatic cancer. Expert Opin Ther Targets. 24:417–426. 2020. View Article : Google Scholar : PubMed/NCBI
45	Kim DH, Triet HM and Ryu SH: Regulation of EGFR activation and signaling by lipids on the plasma membrane. Prog Lipid Res. 83:1011152021. View Article : Google Scholar : PubMed/NCBI
46	Liu G, Xie Y, Su J, Qin H, Wu H, Li K, Yu B and Zhang X: The role of EGFR signaling in age-related osteoporosis in mouse cortical bone. FASEB J. 33:11137–11147. 2019. View Article : Google Scholar : PubMed/NCBI
47	Phukan S, Babu VS, Kannoji A, Hariharan R and Balaji VN: GSK3beta: Role in therapeutic landscape and development of modulators. Br J Pharmacol. 160:1–19. 2010. View Article : Google Scholar : PubMed/NCBI
48	Zhang Z, Lv Z, Zhang W, Guo M and Li C: A novel β-catenin from Apostichopus japonicus mediates Vibrio splendidus-induced inflammatory-like response. Int J Biol Macromol. 156:730–739. 2020. View Article : Google Scholar : PubMed/NCBI